Table 1 Clinical characteristics of 352 patients, stratified according to FGFR1 amplification status, whose tumors were assessable by FISH

From: Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH

 

All patients

FGFR1 FISH amplified

FGFR1 FISH negative

P-value

Median age, years (range)

69 (19–87)

70 (52–84)

69 (19–87)

0.039a

Sex, n=352 (%)

 Male

222 (63)

38 (77.5)

184 (61)

0.025b

 Female

130 (37)

11 (22.5)

119 (39)

 

Smoking, n=352 (%)

 Current

69 (20)

12 (24.5)

57 (19)

0.106

 Former

223 (63)

35 (71.5)

188 (62)

0.040b

 Never

35 (10)

1 (2)

34 (11)

 

 Unknown

25 (7)

1 (2)

24 (8)

 

Stage, n=352 (%)

   

NSa

 Stage IA

83 (24)

12 (24.5)

71 (23)

 

 Stage IB

79 (22)

12 (24.5)

67 (22)

 

 Stage IIA

46 (13)

5 (10)

41 (13.5)

 

 Stage IIB

53 (15)

12 (24.5)

41 (13.5)

 

 Stage IIIA

67 (19)

5 (10)

62 (20)

 

 Stage IIIB

6 (2)

1 (2)

5 (2)

 

 Stage IV

16 (4)

2 (4.5)

14 (5)

 

 Unknown

2 (1)

0

2 (1)

 

N stage, n=313 (%)

   

0.049a

 N0

202 (65)

33 (79)

169 (62)

 

 N1

70 (22)

6 (14)

64 (24)

 

 N2

41 (13)

3 (7)

38 (14)

 
  1. aResults of multivariate analysis examining survival function of patients with tumors with any squamous morphology or immunoprofile.
  2. bThese results refer to the relationships between sex and FGFR1 amplification, and smoking and FGFR1 amplification, respectively, and were only significant when examined in all non-small cell lung carcinoma patients; significance was lost when only patients with tumors with any squamous morphology or immunoprofile were examined.
Back to article page